Formulary Search
Search Results : Depression (Fluoxetine hydrochloride - Depression)
Show Icon and Status Keys
- Capsules
- Dispersible tablets
- Oral solution
Fluoxetine dispersible tablets are the more cost effective option in patents without dysphagia.
Fluoxetine oral solution and dispersible tablets are clinically interchangable for oral use.
- Tablets
- Oral drops
- Tablets
Dose adjustment required for liquid (10mg tablet = 8mg Oral Drops (4 drops) - see SPC for dose equivalence)
- Capsules
- Tablets
- Oral drops
- Oro-dispersible tablets
For use where ordinary tablets are not suitable.
- Tablets
- Oral solution
- Tablets
- Oral suspension
- Tablets
- Oro-dispersible tablets
- Tablets
- Oral solution
Liquid formulation is not cost effective; consider orodispersible tablets.
- Tablets
- Tablets
- Tablets
- Modified release capsules
- Modified release tablets
In Primary Care, OptimiseRx will be used to recommend the most cost-effective formulation at the point of prescribing.
- Tablets
For treating major depressive episodes in line with NICE TA367.
- Oral solution
- Tablets
Initiation and stabilisation by the Mental Health specialist team for a minimum of 3 months before any transfer of prescribing.
Exception - the specialist team may request this treatment is restarted in patients who have previously benefitted.
Not for routine initiation in new patients - risks of toxicity in overdose.
- Capsules
Initiation and stabilisation by the Mental Health specialist team for a minimum of 3 months before any transfer of prescribing.
Not for routine initiation in new patients - risks of toxicity in overdose.
Initiation and stabilisation by the Mental Health specialist team for a minimum of 3 months before any transfer of prescribing.
- Tablets
Initiation and stabilisation by the mental health specialist team for a minimum of 6 months before any transfer of care.
- Not Specified
To be initiated by a specialist.
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the Blue information sheet and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
- Tablets
Initiation and stabilisation by specialist for a minimum of 6 months before any transfer of prescribing responsibility is requested.
- Tablets
Initiation and stabilisation by mental health specialist team for a minimum of 6 months before transfer of prescribing responsibility may be requested.
- Immediate release tablets
Adjunctive treatment of major depression.
Initiation and stabilisation by a SABP specialist for a minimum of 3 months before any request for transfer of prescribing responsibility.
- Modified release tablets
Adjunctive treatment of major depression.
Modified release tablets are reserved for use when immediate release tablets are not suitable.
Modified release quetiapine MAY be continued in Primary Care (after a 3-month period of stabilisation by SABP) where the use of immediate release tablets would risk destabilising the patient.
- Tablets
Initiation and stabilisation by mental health specialist team for a minimum of 6 months before transfer of prescribing responsibility may be requested.
- Tablets
Patients who are established on this treatment for depression, and have been receiving prescriptions in Primary Care, may continue to do so.
- Nasal spray
- Not Specified